SEC Company Response from Avalo Therapeutics, Inc. (AVTX) (CIK 0001534120) (AVTX) — Jun 7, 2017
Avalo Therapeutics, Inc. (AVTX) (CIK 0001534120)
Date: June 7, 2017 · CIK: 0001534120 · Accession: 0001628280-17-006265
AI Filing Summary & Sentiment
File numbers found in text: 333-218252
Show Raw Text
CORRESP 1 filename1.htm Document June 7, 2017 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Healthcare & Insurance 100 F Street, N.E. Washington, D.C. 20549 Attn: Jeffrey Gabor Re: Cerecor Inc. Registration Statement on Form S-3 File No. 333-218252 Acceleration Request Requested Date: Friday, June 9, 2017 Requested Time: 4:30 P.M. Eastern Standard Time Ladies and Gentlemen: In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the “Registrant”) hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement on Form S-3 (File No. 333-218252) (the “Registration Statement”) to become effective on Friday, June 9, 2017, at 4:30 p.m. Eastern Standard Time, or as soon thereafter as is practicable, or at such later time as the Registrant may orally request via telephone call to the staff (the “Staff”). Once the Registration Statement has been declared effective, please orally confirm that event with Brent B. Siler of Cooley LLP, counsel to the Registrant, at (202) 728-7040, or in his absence, Madison Jones at (202) 728-7087. [Signature page follows] Very truly yours, Cerecor Inc. By: /s/ Mariam E. Morris Mariam E. Morris Chief Financial Officer cc: Uli Hacksell, Ph.D., Cerecor Inc. Brent B. Siler, Cooley LLP